Identification of current smokers among renal transplant recipients

Nguyen, Pauline; Galanti, Laurence; Pirson, Yves; Jadoul, Michel

doi:10.1093/ndt/gfl849

Cited by 19 publications

(11 citation statements)

References 17 publications

(19 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although this sobering truth may be shocking, these data are comparable to the 21% respectively 25% of heart and renal transplant recipients testing positive for posttransplant smoking [6,7]. Risk factors for post-LTx smoking were a shorter pre-LTx smoking cessation period, emphysema, lower socioeconomic status, ever being widowed and passive smoking.…”

mentioning

confidence: 71%

Smoking resumption after lung transplantation: a sobering truth

Vos¹,

Vusser²,

Schaevers³

et al. 2010

European Respiratory Journal

View full text Add to dashboard Cite

mentioning

confidence: 71%

Smoking resumption after lung transplantation: a sobering truth

Vos¹,

Vusser²,

Schaevers³

et al. 2010

European Respiratory Journal

View full text Add to dashboard Cite

“…In terms of assessment, only 40 studies (54.8%) reported how they measured smoking, with patient self-report being the most common measurement method (n = 26, ie, 35.6%) and only 6 studies using biomarkers of tobacco exposure (eg, serum and urinary cotinine levels, carboxyhemoglobin levels). [24][25][26][27] Only 22 studies (28.8%) mentioned smoking type, of which the majority (n = 21, 95.5%) referred to cigarettes. Most studies looked at sustained smoking or relapse, whereas only 1 study investigated new-onset posttransplant smoking exclusively (excluding patients with a history of smoking pretransplant).…”

Section: Study Characteristicsmentioning

confidence: 99%

Correlates and Outcomes of Posttransplant Smoking in Solid Organ Transplant Recipients

et al. 2016

View full text Add to dashboard Cite

show abstract

“…Screening patients includes asking them about their tobacco use history (including start and stop dates), amounts and types of tobacco used and prior interventions. Patients may not admit that they use tobacco, and nicotine levels have been used to identify smokers among KTRs (589). However, there is insufficient evidence for or against the use of laboratory testing to detect tobacco use in KTRs or in the general population.…”

Section: Rationalementioning

confidence: 99%

Special Issue: KDIGO Clinical Practice Guideline for the Care of Kidney Transplant Recipients

Eckardt¹,

Kasiske²,

Zeier³

2009

American Journal of Transplantation

1,169

294

View full text Add to dashboard Cite

Journal compilation © 2009 The American Society of Transplantation and the American Society of Transplant Surgeons doi: 10.1111/j.1600-6143.2009.02834.x S2 American Journal of Transplantation 2009; 9 (Suppl 3): S2-S2Since the first successful kidney transplantation in 1954 It is our hope that this document will serve several useful purposes. Our primary goal is to improve patient care. We hope to accomplish this in the short term by helping clinicians know and better understand the evidence (or lack of evidence) that determines current practice. By making this guideline broadly applicable, our purpose is to also encourage and enable the establishment and development of transplant programs worldwide. Finally, by providing comprehensive evidence-based recommendations, this guideline will also help define areas where evidence is lacking and research is needed. Helping to define a research agenda is an often neglected, but very important function of clinical practice guideline development.We used the GRADE system to rate the strength of evidence and the strength of recommendations. In all, there were only 4 (2%) recommendations in this guideline for which the overall quality of evidence was graded 'A,' whereas 27 (13.6%) were graded 'B,' 77 (38.9%) were graded 'C,' and 90 (45.5%) ' and 148 (74.7%) graded '2.' There were 3 (1.5%) recommendations graded '1A,' 16 (8.1%) were '1B,' 18 (9.1%) were '1C, ' and 13 (6.6%) were '1D.' There was 1 (0.5%) graded '2A,' 11 (5.6%) were '2B,' 59 (29.8%) were '2C, ' and 77 (38.9%) BackgroundExcept perhaps for transplantation between identical twins, all kidney transplant recipients (KTRs) need immunosuppressive medications to prevent rejection. Induction therapy is treatment with a biologic agent, either a lymphocyte-depleting agent or an interleukin 2 receptor antagonist (IL2-RA), begun before, at the time of, or immediately after transplantation. The purpose of induction therapy is to deplete or modulate T-cell responses at the time of antigen presentation. Induction therapy is intended to improve the efficacy of immunosuppression by reducing acute rejection, or by allowing a reduction of other components of the regimen, such as calcineurin inhibitors (CNIs) or corticosteroids. Available lymphocytedepleting agents include antithymocyte globulin (ATG), antilymphocyte globulin (ALG) and monomurab-CD3. Basiliximab and daclizumab, the two IL2-RAs that are currently available in many parts of the world, bind the CD25 antigen (interleukin-2 [IL2] receptor a-chain) at the surface of activated T-lymphocytes and thereby competitively inhibit IL2-mediated lymphocyte activation, a crucial phase in cellular immune response of allograft rejection. Rationale• There is high-quality evidence that the benefits of IL2-RA vs. no IL2-RA (or placebo) outweigh harm in a broad range of KTRs with variable immunological risk and concomitant immunosuppressive medication regimens.• There is moderate-quality evidence that a lymphocytedepleting agent vs. no lymphocyte-depleting a...

show abstract

Identification of current smokers among renal transplant recipients

Cited by 19 publications

References 17 publications

Smoking resumption after lung transplantation: a sobering truth

Smoking resumption after lung transplantation: a sobering truth

Correlates and Outcomes of Posttransplant Smoking in Solid Organ Transplant Recipients

Special Issue: KDIGO Clinical Practice Guideline for the Care of Kidney Transplant Recipients

Contact Info

Product

Resources

About